Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?
Pierre Frange, Roland Tubiana, Jeanne Sibiude, Ana Canestri et autres
BACKGROUND: Safety data about rilpivirine use during pregnancy remain scarce, and rilpivirine plasma concentrations are reduced during second/third trimesters, with a potential risk of viral breakthroughs. Thus, French guidelines recommend switching to rilpivirine-free combinations (RFCs) during pregnancy. OBJECTIVES: To describe the characteristics …
fr, gb (code pays fourni par la source)